<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02254629</url>
  </required_header>
  <id_info>
    <org_study_id>2014SDU-QILU-G04</org_study_id>
    <nct_id>NCT02254629</nct_id>
  </id_info>
  <brief_title>The Effects of Laxative-probiotic Sequential Treatment in the Irritable Bowel Syndrome Patients</brief_title>
  <official_title>The Effects of Laxative-probiotic Sequential Treatment on the Symptoms and Fecal Microbiota in the IBS Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      the laxative-probiotic sequential treatment might reduce the symptoms of IBS and alter the
      fecal microbiota of the patients in a more robust manner .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Probiotics can regulate intestinal immunity, repair mucosal barrier, and reportedly exert
      therapeutic effects on IBS patients. The laxatives could also alter the gut microflora
      significantly, thus the laxative-probiotic sequential treatment might affect the symptoms and
      the composition of fecal microbiota in the IBS patients in a more robust manner .
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject's Global Assessment of Relief</measure>
    <time_frame>8 months</time_frame>
    <description>The SGA (subjective global assessment) of Relief was assessed by answering the following question: &quot;Please consider how you felt this past week in regard to your IBS, in particular your overall wellbeing, symptoms and altered bowel habit. Compared to the way you usually felt before entering the study, how would you rate your relief of symptoms during the past week?&quot; The scale contained five possible answers: (1) completely relieved, (2) considerably relieved, (3) somewhat relieved, (4) unchanged, or (5) worse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The changes of symptom scores</measure>
    <time_frame>8 months</time_frame>
    <description>The symptom score includes abdominal pain, discomfort, bloating, stool frequency, stool consistency according to Bristol stool form scale and defecation urgency，imcomplete，straining.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IBS patients'quality of life</measure>
    <time_frame>8 months</time_frame>
    <description>Quality of life was determined by using IBS-QOL scoring system for patients with IBS. This questionnaire comprises a range of 34 items with response options on a 5-point rating scale. The items contribute to 8 domains as follows: Dysphoria, Interference with activity, Body image, Health worry, Food avoidance, Social reaction, Sexual, Relationship.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composition of Microorganisms in stool</measure>
    <time_frame>8 months</time_frame>
    <description>Primary coordination of fecal samples' 16s rDNA (ribosomal deoxyribonucleic acid) will be compared between two Groups using Braycurtis distance based Primary coordination analysis (PCoA).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>laxative-probiotic sequential</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>laxative：2000 ml. Probiotic：2 tablets/ times, 3 times / day for the first 2 weeks，immediately after colonoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>probiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Probiotic：2 tablets/ times, 3 times / day for the first 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laxative followed by Probiotic 2 weeks later</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>laxative：2000 ml. Probiotic：2 tablets/ times, 3 times / day for the last 2 weeks with two weeks interval after colonoscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probiotic Clostridium Butyricum</intervention_name>
    <description>probiotic:2 tablets/ times, 3 times / day for 2 weeks</description>
    <arm_group_label>laxative-probiotic sequential</arm_group_label>
    <arm_group_label>probiotic</arm_group_label>
    <arm_group_label>Laxative followed by Probiotic 2 weeks later</arm_group_label>
    <other_name>Clostridium Butyricum Tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Laxative Polyethylene Glycol</intervention_name>
    <description>laxative：2000 ml.</description>
    <arm_group_label>laxative-probiotic sequential</arm_group_label>
    <arm_group_label>Laxative followed by Probiotic 2 weeks later</arm_group_label>
    <other_name>Polyethylene Glycol Electrolytes Powder.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  the presence of Rome III criteria for IBS ;

          -  Patients scheduled for colonoscopy examination or having negative screening
             examinations

          -  Aged between 18 and 65 years old

        Exclusion Criteria:

          -  Antibiotic, probiotic or laxative usage within 4 weeks.

          -  organic gastrointestinal diseases

          -  Severe systematic disease: diabetes mellitus, hepatic, renal or cardiac dysfunction,
             thyroid disease or tumor etc.

          -  pregnancy or lactation.

          -  previous major or complicated abdominal surgery.

          -  severe endometriosis and dementia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanqing Li, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital，Shandong University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yanqing Li, MD.PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital, Shandong University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Gastroenterology, Qilu Hospital, Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2014</study_first_submitted>
  <study_first_submitted_qc>October 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2014</study_first_posted>
  <last_update_submitted>August 30, 2016</last_update_submitted>
  <last_update_submitted_qc>August 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Yanqing Li</investigator_full_name>
    <investigator_title>Vice president of Qilu Hospital</investigator_title>
  </responsible_party>
  <keyword>Fecal microflora</keyword>
  <keyword>IBS</keyword>
  <keyword>Sequential treatment</keyword>
  <keyword>Probiotic</keyword>
  <keyword>Laxative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Laxatives</mesh_term>
    <mesh_term>Cathartics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

